Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 22, Issue 3, 2011, Pages 88-96

  Klein, Marina B ^a   Baril, Jean Guy ^b,c,d   Charron, Marc André ^b,c   Fortin, Claude ^e   Lalonde, Richard ^a   Matte, Marie France ^f   Poliquin, Marc ^e   Talbot, Annie ^b,c   Therrien, Rachel ^c   Tremblay, Cécile ^c,g   Trottier, Benoît ^c,h   Tsarevsky, Irina ^d   Villeneuve, Jean Pierre ⁱ  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Clinique Medicale du Quartier Latin   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Ministere de la Sante et des Services Sociaux   (Canada)

^e NOTRE DAME HOSPITAL   (Canada)

^f Programme National de Mentorat Sur le VIH Sida   (Canada)

^g Association des Médecins Microbiologistes Infectiologues du Québec   (Canada)

^h Clinique Medicale l'Actuel   (Canada)

ⁱ UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Antiretroviral therapy; Hepatitis B; HIV; HIV coinfection; Resistance; Vaccination

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE;

CANCER SCREENING; ESOPHAGUS VARICES; FOLLOW UP; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PRACTICE GUIDELINE; REVIEW; VACCINATION;

EID: 80052729124     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/686918     Document Type: Review

References (97)

1. Alter M. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(Supp 1):S6-S9. (Pubitemid 43053865)
2. Konopnicki D, Mocroft A, De Wit S, et al; EuroSIDA Group. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005;19:593-601. (Pubitemid 40543982)
3. Trottier B, Thomas R, Machouf N; International Conference on AIDS. How well do we manage HIV infection in intravenous drug users (IDU). Int Conf AIDS 2004;15.
4. Bamvita J-M. Évolution de la mortalité dans une cohorte de patients VIH positifs de la CMQL, 2007.
5. Gatanaga H, Yasuoka A, Kikuchi Y, Tachikawa N, Oka S. Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. Eur J Clin Microbiol Infect Dis 2000;19:237-9. (Pubitemid 30201305)
6. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: A cohort study and meta-analysis. Clin Infect Dis 2009;48:1763-71.
7. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603. (Pubitemid 15102154)
8. De Franchis R, Hadengue A, Lau G, et al EASL Jury. EASL International Consensus Conference on Hepatitis B. J Hepatol 2003;39(Suppl 1):S3-25.
9. Bowden S. Serological and molecular diagnosis. Semin Liver Dis 2006;26:97-103. (Pubitemid 43668252)
10. Douglas DD, Taswell HF, Rakela J, Rabe D. Absence of hepatitis B virus DNA detected by polymerase chain reaction in blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of hepatitis B serologic markers. Transfusion 1993;3:212-6. (Pubitemid 23073643)
11. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-8. (Pubitemid 11123366)
12. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986;90:1268-73. (Pubitemid 16145494)
13. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-91. (Pubitemid 19216208)
14. UpToDate. Serologic responses to HBV infection. (Accessed on November 4, 2009).
15. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-9. (Pubitemid 13224257)
16. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6:167-72. (Pubitemid 16144862)
17. Lo Re V III, Frank I, Gross R, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007;44:315-20. (Pubitemid 46328349)
18. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40.
19. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 1997;11:597-606. (Pubitemid 27135881)
20. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123:1812-22. (Pubitemid 35408305)
21. Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: Case series and review of the literature. AIDS 2007;21:771-4. (Pubitemid 46568638)
22. Hofer M, Joller-Jemelka HI, Grob PJ, Lüthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998;17:6-13. (Pubitemid 28072282)
23. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004;36:869-75. (Pubitemid 38859354)
24. Peters M. Diagnosis and management of hepatitis B virus and HIV coinfection. Top HIV Med 2007;15:163-6.
25. Núñez M. Routine hepatitis B virus DNA testing in human immunodeficiency virus-infected patients with positive hepatitis B core antibody but negative hepatitis B surface antigen is not justified by current evidence. Hepatology 2010;51:1087-8.
26. Comité consultatif national de l'immunisation. Guide canadien d'immunisation. 7ème édition ed. Ottawa: Agence de la santépublique du Canada, 2006.
27. Comité sur l'immunisation du Québec. Protocole d'immunisation du Québec. Ministère de la Santé et des Service sociaux, 2004.
28. British HIV Association. HIV and chronic hepatitis: Co-infection with HIV and hepatitis virus infection. British HIV Association, 2004.
29. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000;18:1161-5. (Pubitemid 30001829)
30. Fonseca MO, Pang LW, De Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients: Comparing a standard dose to a double dose. Vaccine 2005;23:2902-8. (Pubitemid 40386492)
31. Pasricha N, Datta U, Chawla Y, et al. Immune responses in patients with HIV infection after vaccination with recombinant hepatitis B virus vaccine. BMC Infect Dis 2006;6:65.
32. Cornejo-Juárez P, Volkow-Fernández P, Escobedo-López K, et al. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients: Comparing two different doses. AIDS Res Ther 2006;6:9.
33. Ungulkraiwit P, Jongjirawisan Y, Atamasirikul K, Sungkanuparph S. Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients. Southeast Asian J Trop Med Public Health 2007;38:680-5.
34. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006;24:7124-8. (Pubitemid 46107206)
35. Wilson CM, Ellenberg JH, Sawyer MK, et al; Adolescent Medicine HIV/AIDS Research Network. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the Reaching for Excellence in Adolescent Care and Health cohort (REACH). J Adolesc Health 2001;29(3 Suppl):123-9. (Pubitemid 32799168)
36. Piroth L, Grappin M, Buisson M, Duong M, Portier H, Chavanet P. Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23:356-7. (Pubitemid 30327040)
37. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity. Lancet 2000;355:561-5.
38. Brook MG, Gilson R, Wilkins E; BHIVA Hepatitis Coinfection Guideline Committee; British HIV Association. BHIVA guidelines on HIV and chronic hepatitis: Coinfection with HIV and hepatitis B virus infection. HIV Medicine 2005;6(Suppl 2):84-95. (Pubitemid 41038587)
39. Kelleher TB, Afdhal N. Assessment of liver fibrosis in coinfected patients. J Hepatol 2006;44(Suppl 1):S126-S131. (Pubitemid 43053888)
40. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39:222-40.
41. Ziol M, Handra-Luca A, Kettaneh A, et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54. (Pubitemid 40066382)
42. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48:835-47.
43. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007;21:2209-16. (Pubitemid 350287219)
44. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009;29:242-7.
45. Bárcena Marugán R, García Garzón S. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol 2009;15:423-30.
46. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel. AIDS 2005;19:221-40. (Pubitemid 40396554)
47. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: Consensus guidelines. Can J Gastroenterol 2007;21(Suppl C):5C-24C. (Pubitemid 47162250)
48. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994;21:656-66. (Pubitemid 24324044)
49. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-7. (Pubitemid 29215551)
50. Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. J Hepatol 2007;47:527-37. (Pubitemid 47334759)
51. Laboratoire de santé publique du Québec (LSPQ). Registre MADO dépersonnalisé. Extraction au registre fait par le Bureau de Surveillance et de Vigie (MSSS), 2007.
52. Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661-2.
53. Garcia-Tsao G. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-38. (Pubitemid 47436138)
54. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Accessed on February 22, 2011).
55. Rouleau D, Fortin C, Trottier B, et al. Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec care committee. Can J Infect Dis Med Microbiol 2010;21.
56. Núñez M, Ramos B, Díaz-Pollán B, et al. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses 2006;22:842-8. (Pubitemid 44757159)
57. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-6. (Pubitemid 44748362)
58. Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006;20:1951-4. (Pubitemid 44427612)
59. Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005;56:1087-93. (Pubitemid 43009825)
60. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6. (Pubitemid 29510871)
61. Johnson RM, Ristig MB, Overton ET, Lisker-Melman M, Cummings OW, Aberg JA. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV Clin Trials 2007;8:173-81. (Pubitemid 47121762)
62. Sheldon JA, Corral A, Rodés B, et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005;19:2036-8. (Pubitemid 41669031)
63. Di Martino V, Thevenot T, Boyer N, et al. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS 2002;16:441-5. (Pubitemid 34165376)
64. Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. AIDS 2009;23:546-7.
65. Avila C, Karwowska S, ChingHa L, Evans TG. Telbivudine has no in vitro activity against laboratory and clinical HIV-1, including 5 clades and drug-resistant clinical isolates. 16th CROI Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009.
66. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-3. (Pubitemid 19270158)
67. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301. (Pubitemid 20237094)
68. Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-7.
69. Janssen HLA. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005;365:123-9. (Pubitemid 40091801)
70. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
71. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-30. (Pubitemid 35403533)
72. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: Genotype A is more sensitive to interferon than genotype D. Gut 2005;54:1009-13. (Pubitemid 40873918)
73. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-5. (Pubitemid 29203534)
74. Wursthorn K, Buggisch P, Lutgehetmann M, Zollner B, Petersen J. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV. Antivir Ther 2006;11:647-52. (Pubitemid 44277431)
75. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), HIV Medicine Association of the Infectious Diseases Society of America (HIVMA/IDSA). Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, 2008:302.
76. AHFS Drug Information. Monograph - peginterferon alpha. American Society of Health-System Pharmacists, 2007.
77. Gilead Sciences. Product Monograph: PrViread (Tenofovir Disoproxil Fumarate Tablets), 2009.
78. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001;358:718-23. (Pubitemid 32823401)
79. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxyl for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81. (Pubitemid 41007822)
80. Delaney WE IV, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003;77:11833-41. (Pubitemid 37271680)
81. Warner N, Locarnini S, Kuiper M, et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007;51:2285-92. (Pubitemid 47047302)
82. Bozdayi AM, Uzunalimoglu O, Türkyilmaz AR, et al. YSDD: A novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hep 2003;10:256-65. (Pubitemid 36801911)
83. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-13. (Pubitemid 46374587)
84. Westland CE, Yang H, Delaney WE IV, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hep 2005;12:67-73. (Pubitemid 40188776)
85. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-9. (Pubitemid 43260045)
86. Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hep 2006;13:250-5.
87. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209. (Pubitemid 41446860)
88. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003;17:F7-F10. (Pubitemid 36106292)
89. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51. (Pubitemid 44958517)
90. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7. (Pubitemid 36929407)
91. Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006;20:2229-31. (Pubitemid 44684715)
92. Colonno RJ, Rose RE, Pokornowski K, et al. Four year assessment of ETV resistance in nucleoside-naïve and lamivudine refractory patients. April 11-15, 2007.
93. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-21. (Pubitemid 46961006)
94. Colonno RJ. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006;44(S1):229A-30A.
95. The Globe Study Group. 2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95.
96. Van Bömmel F, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002;36:507-8. (Pubitemid 34810374)
97. Van Bömmel F, Zöllner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318-25. (Pubitemid 44214870)